July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]
July 29, 2024
Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]
July 29, 2024
ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]
July 9, 2024
By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]
July 9, 2024
By Ronak Rajani, Roberta Lima Brum, and Vitaliy Androshchuk HIV affects approximately 45 million people worldwide, making it a major ongoing public health challenge. Although antiretroviral […]
April 3, 2024
By Kathleen V. Fitch, Marissa Diggs, and Steve Grinspoon Due to the remarkable strides in the management and support of PWH, life expectancy now almost parallels […]
March 14, 2024
By Keith Alcorn The REPRIEVE study of pitavastatin for prevention of cardiovascular disease showed that statins reduced the risk of major cardiovascular events such as heart attack […]
March 13, 2024
On Tuesday at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with NIH’s Dr. Carl Dieffenbach about research on common health complications of […]
March 4, 2024
The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and […]
July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]
July 29, 2024
Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]
July 29, 2024
ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]
July 9, 2024
By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]
July 9, 2024
By Ronak Rajani, Roberta Lima Brum, and Vitaliy Androshchuk HIV affects approximately 45 million people worldwide, making it a major ongoing public health challenge. Although antiretroviral […]
April 3, 2024
By Kathleen V. Fitch, Marissa Diggs, and Steve Grinspoon Due to the remarkable strides in the management and support of PWH, life expectancy now almost parallels […]
March 14, 2024
By Keith Alcorn The REPRIEVE study of pitavastatin for prevention of cardiovascular disease showed that statins reduced the risk of major cardiovascular events such as heart attack […]
March 13, 2024
On Tuesday at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with NIH’s Dr. Carl Dieffenbach about research on common health complications of […]
March 4, 2024
The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and […]